secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001055726-25-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025
--------------------------------------------------------------------------------

- Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.
- Cash and short-term investments $68.4M as of Mar 31, 2025, down from $94.1M at Dec 31, 2024.
- On track to begin rolling BLA submission for INO-3107 (RRP) in mid-2025; FDA acceptance targeted by year-end.
- DMAb Phase 1 trial: 100% of participants (24/24) at week 72 maintained antibody levels; no anti-drug antibodies.
- R&D expenses decreased to $16.1M from $20.9M; net cash burn guidance ~$22M for Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/0001055726-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001055726-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer